News

Murray appointed chief product officer at Catalina

BY Allison Cerra

ST. PETERSBURG, Fla. — Catalina Marketing has appointed its first-ever chief product officer.

Michael Murray, former Sears Holdings chief marketing officer of e-commerce and online, brings more than 20 years of experience in the areas of data and information technology, product development, marketing and business management, including pioneering new media and internet solutions, to his new role. At Catalina, Murray is responsible for leading the company’s overall consumer-centric product strategy and innovation roadmap. He also will play a pivotal role in the company’s expanding portfolio of breakthrough products and solutions that help brands and retailers better engage today’s connected consumer—online and offline, the company said.

"Catalina is dramatically expanding its vision and solutions to address the changing needs of brands, retailers and consumers. We’re bringing new personalized experiences to consumers across a variety of touch points along the path-to-purchase and helping our clients grow consumer loyalty over time," Catalina CEO Jamie Egasti said. "Michael is an accomplished executive with extensive innovation experience across traditional and new media marketing, CRM, and Internet technology. His experience in driving innovation, as well as expertise in when and how to engage the consumer along the path-to-purchase, will help Catalina stay at the forefront of consumer loyalty innovation."

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

News

PriceGrabber: Shoppers to spend same on Dad as they did Mom

BY Allison Cerra

LOS ANGELES — Most shoppers plan to spend the same amount of money for Father’s Day as they did for Mother’s Day, a new PriceGrabber survey revealed.

Polling 4,450 U.S. online shopping consumers, the survey found that 70% of shoppers plan to show Dad equal love this year, with 57% planning to spend less than $100 on gifts, 21% planning to spend between $100 and $249, 11% planning to spend more than $249 and an additional 11% saying they have no set budget when purchasing Father’s Day gifts this year.

But as more than half (56%) said they will from online stores via their computers — followed by 36% who plan to buy in brick-and-mortar stores and just 2% of survey respondents saying they plan to purchase gifts from an online store via a mobile device — what will motivate consumers to buy a product or service for Dad is free shipping (59%), price cuts (48%), sales (42%) and coupons (36%). Eighteen percent of shoppers said they will not be influenced by retailer tactics.

"Consumers are still budget conscience and will look for deals when Father’s Day shopping this year," PriceGrabber general manager Graham Jones said. "Even though most shoppers plan to spend under $100 on their Dad this year based on our survey data, it’s not surprising to see that retailer tactics such as free shipping, price cuts, sales and coupons will help sweeten the deal when enticing consumers to buy gifts for Dad this holiday."

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

News

Bayer gastrointestinal cancer drug extends progression-free survival in trial

BY Alaric DeArment

WAYNE, N.J. — An experimental drug made by Bayer HealthCare extended the length of time that patients with gastrointestinal tumors survived without their disease getting worse, according to results of a late-stage clinical trial released Monday.

Bayer announced the release of data from the phase-3 "GRID" trial of regorafenib in patients with gastrointestinal stromal tumors, also known as GIST, whose tumors could not be removed through surgery or whose disease had spread to other parts of the body despite prior treatment with Novartis’ Gleevec (imatinib). The trial compared the ability of regorafenib to extend progression-free survival of patients with that of placebo.

According to the results, which the study’s investigators plan to present at the American Society of Clinical Oncology’s 48th annual meeting in Chicago, patients taking the drug experienced progressive-free survival of nearly five months, compared with just under a month among those taking placebo.


Interested in this topic? Sign up for our weekly DSN Collaborative Care e-newsletter.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES